Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14197457 | 0.85 | HRH1 (0.49) | HRH1DRD2DRD4CREBBPHDAC6 | |
| SCHEMBL4862162 | 0.77 | HRH1 (0.49) | HRH1DRD2DRD4CREBBPHDAC6 | |
| Fumaric Acid SCHEMBL7647902 | 0.76 | HRH1 (0.44) | HRH1DRD2DRD4CREBBPHDAC6 | |
| Fumaric Acid SCHEMBL5017861 | 0.76 | HRH1 (0.44) | HRH1DRD2DRD4CREBBPHDAC6 | |
| Fumaric Acid SCHEMBL5017856 | 0.76 | HRH1 (0.44) | HRH1DRD2DRD4CREBBPHDAC6 | |
| Fumaric Acid SCHEMBL7647905 | 0.76 | HRH1 (0.44) | HRH1DRD2DRD4CREBBPHDAC6 | |
| SCHEMBL14197429 | 0.74 | HRH1 (0.52) | HRH1DRD2HDAC6 | |
| SCHEMBL17075141 | 0.73 | ALDH1A1 (0.39) | DRD2DRD4CYP2C19CREBBPCHRM2 | |
| SCHEMBL11359103 | 0.73 | HRH1 (0.58) | HRH1DRD2DRD4CREBBPHDAC6 | |
| SCHEMBL14197432 | 0.73 | HRH1 (0.48) | HRH1DRD2DRD4CREBBPHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351839-B2 | Process for the preparation of 1,2,3,4,8,9,10, 10a-octahydro-7bH-cyclopenta[b][1,4]diazepino-[6,7,1-hi]indole derivatives | WYETH (US) | 2008-04-01 | — | — | US | claimed |
| US-20070066676-A1 | Process for the preparation of 1,2,3,4,8,9,10, 10a-octahydro-7bH-cyclopenta[b][1,4]diazepino-[6,7,1-hi]indole derivatives | WYETH (US) | 2007-03-22 | — | — | US | claimed |
| EP-1330457-B1 | CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS | WYETH CORP (US) | 2004-10-20 | — | — | EP | claimed |
| EP-1330457-A2 | CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS | Wyeth (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2002042304-A2 | CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS | WYETH (US) | 2002-05-30 | — | — | WO | claimed |
| US-20020058689-A1 | Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi]indole derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-05-16 | — | — | US | claimed |
| US-7351839-B2 | Process for the preparation of 1,2,3,4,8,9,10, 10a-octahydro-7bH-cyclopenta[b][1,4]diazepino-[6,7,1-hi]indole derivatives | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351839-B2 | Process for the preparation of 1,2,3,4,8,9,10, 10a-octahydro-7bH-cyclopenta[b][1,4]diazepino-[6,7,1-hi]indole derivatives | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080009480-A1 | CYCLOPENTA[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES | WYETH (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009480-A1 | CYCLOPENTA[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES | WYETH (US) | 2008-01-10 | — | — | US | disclosed |
| US-7271163-B2 | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | WYETH (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271163-B2 | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | WYETH (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070066676-A1 | Process for the preparation of 1,2,3,4,8,9,10, 10a-octahydro-7bH-cyclopenta[b][1,4]diazepino-[6,7,1-hi]indole derivatives | WYETH (US) | 2007-03-22 | — | — | US | disclosed |
| EP-1330457-B1 | CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS | WYETH CORP (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6777407-B2 | 7BH-CYCLOPENTA(B)(1,4)DIAZEPINO(6, 7, 1-HI)INDOLE OR A SALT, USEFUL FOR TREATMENT OF SCHIZOPHRENIA, OBSESSIVE COMPULSIVE DISORDER, DEPRESSION, ANXIETY, PANIC DISORDER, OBESITY OR EPILEPSY | WYETH | 2004-08-17 | — | — | US | disclosed |
| US-6777407-B2 | 7BH-CYCLOPENTA(B)(1,4)DIAZEPINO(6, 7, 1-HI)INDOLE OR A SALT, USEFUL FOR TREATMENT OF SCHIZOPHRENIA, OBSESSIVE COMPULSIVE DISORDER, DEPRESSION, ANXIETY, PANIC DISORDER, OBESITY OR EPILEPSY | WYETH | 2004-08-17 | — | — | US | disclosed |
| EP-1330457-A2 | CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS | Wyeth (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20020107242-A1 | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-08 | — | — | US | disclosed |
| WO-2002042304-A2 | CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS | WYETH (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020058689-A1 | Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi]indole derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107242-A1 | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | CNR1, HCRTR1, HTR3C | HRH1 136/4885DRD2 48/4885DRD4 161/4885 |
| US-20020058689-A1 | Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi]indole derivatives | HRH3, HTR1A, HTR7 | HRH1 5/4885DRD2 69/4885DRD4 86/4885 |
| US-20070066676-A1 | Process for the preparation of 1,2,3,4,8,9,10, 10a-octahydro-7bH-cyclopenta[b][1,4]diazepino-[6,7,1-hi]indole derivatives | HRH4, HRH3, AHR | HRH1 4/4885DRD2 60/4885DRD4 69/4885 |
| US-20080009480-A1 | CYCLOPENTA[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES | CNR1, HCRTR1, HTR3C | HRH1 62/4885DRD2 40/4885DRD4 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.